TRAF2 Inhibitors
TRAF2 inhibitors are a specialized class of chemical compounds designed to selectively target and inhibit the activity of the TNF receptor-associated factor 2 (TRAF2) protein. TRAF2 is a critical adaptor protein involved in signal transduction pathways that regulate various cellular responses, including apoptosis, inflammation, and immune signaling. As a key mediator in the TNF receptor superfamily, TRAF2 plays an essential role in the activation of NF-κB and JNK pathways, which are pivotal for controlling gene expression in response to external stimuli. By inhibiting TRAF2, researchers can disrupt these signaling pathways, allowing for the exploration of TRAF2's specific functions and its contributions to cellular processes such as survival, proliferation, and stress responses.
In research, TRAF2 inhibitors are valuable tools for probing the intricate mechanisms of signal transduction. By blocking TRAF2 activity, scientists can dissect the role of this adaptor protein in the broader context of cellular signaling networks. These inhibitors help to clarify how TRAF2 interacts with other signaling molecules and the downstream effects of its inhibition, such as the modulation of NF-κB and JNK activity. This is particularly important in understanding how cells respond to cytokines, stress, and other environmental factors that influence immune and inflammatory responses. Furthermore, TRAF2 inhibitors enable researchers to investigate the cross-talk between different signaling pathways and how the disruption of TRAF2 affects the overall cellular response. By studying these effects, scientists gain insights into the complex regulatory mechanisms that govern cellular behavior and the critical role that TRAF2 plays in maintaining cellular homeostasis and responding to external challenges.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CDDO Imidazolide | 443104-02-7 | sc-504719 | 1 mg | $700.00 | ||
CDDO-Im, a synthetic triterpenoid, indirectly inhibits TRAF2 by targeting the NF-κB pathway. Through inhibition of IKKβ and suppression of NF-κB activation, CDDO-Im disrupts TRAF2-mediated signaling, impacting cellular responses related to inflammation and apoptosis. The compound provides an avenue to selectively modulate TRAF2 activity by targeting the NF-κB pathway. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1, an inhibitor of IKK-2, indirectly influences TRAF2 by disrupting the NF-κB pathway. Inhibition of IKK-2 activity prevents NF-κB activation, impacting TRAF2-mediated signaling and cellular responses related to inflammation and apoptosis. TPCA-1 provides a specific means to modulate TRAF2 activity by targeting the NF-κB pathway, highlighting the intricate crosstalk between NF-κB and TRAF2. | ||||||
(5Z)-7-Oxozeaenol | 253863-19-3 | sc-202055 sc-202055A | 1 mg 5 mg | $157.00 $646.00 | 13 | |
5Z-7-Oxozeaenol, an inhibitor of TAK1, indirectly influences TRAF2 by disrupting the TAK1-MKK3/6-p38 MAPK pathway. Inhibition of TAK1 prevents downstream MAPK activation, impacting TRAF2-mediated signaling and cellular responses related to inflammation and apoptosis. 5Z-7-Oxozeaenol provides a specific means to modulate TRAF2 activity through the TAK1-MAPK pathway, illustrating the intricate interplay between these signaling modules. | ||||||
Tanshinone IIA | 568-72-9 | sc-200932 sc-200932A | 5 mg 25 mg | $88.00 $316.00 | 22 | |
Tanshinone IIA, a bioactive compound from Salvia miltiorrhiza, serves as a TRAF2 inhibitor by affecting the NF-κB pathway. Inhibition of IKKβ disrupts NF-κB activation, influencing TRAF2 expression and function, altering cellular responses related to inflammation and apoptosis. Tanshinone IIA's selective impact on NF-κB signaling positions it as a valuable tool for investigating the crosstalk between inflammatory and apoptotic pathways converging on TRAF2. | ||||||
Ursolic Acid | 77-52-1 | sc-200383 sc-200383A | 50 mg 250 mg | $56.00 $180.00 | 8 | |
Ursolic acid, a natural pentacyclic triterpenoid, indirectly inhibits TRAF2 by modulating the NF-κB pathway. Inhibition of IKKβ disrupts NF-κB activation, influencing TRAF2 expression and function, altering cellular responses related to inflammation and apoptosis. Ursolic acid's selective impact on NF-κB signaling positions it as a valuable tool for investigating the crosstalk between inflammatory and apoptotic pathways converging on TRAF2. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23, an inhibitor of nuclear translocation of NF-κB, indirectly influences TRAF2 by disrupting the NF-κB pathway. Inhibition of NF-κB nuclear translocation impacts TRAF2-mediated signaling and cellular responses related to inflammation and apoptosis. JSH-23 provides a specific means to modulate TRAF2 activity by targeting the NF-κB pathway, highlighting the intricate crosstalk between NF-κB and TRAF2. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
SC-514, an inhibitor of IKK-2, indirectly influences TRAF2 by disrupting the NF-κB pathway. Inhibition of IKK-2 activity prevents NF-κB activation, impacting TRAF2-mediated signaling and cellular responses related to inflammation and apoptosis. SC-514 provides a specific means to modulate TRAF2 activity by targeting the NF-κB pathway, illustrating the intricate crosstalk between NF-κB and TRAF2. | ||||||